BioPharmSignal logoBioPharmSignal

Biotech News

Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update

Spero Therapeutics (SPRO)Spero TherapeuticsEarnings

Spero announced the resubmission of tebipenem HBr New Drug Application (NDA) to the FDA for complicated urinary tract infections (cUTI), including pyelonephritis in December 2025

In February, Spero's licensing partner, GSK announced the FDA had set the PDUFA date as June 18, 2026

Spero...

Related news

SPROSpero Therapeutics2026-08-12 21:01 EST

Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update

SPROSpero Therapeutics2026-05-13 21:05 EST

Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update

VIRIVirios Therapeutics2026-03-18 12:30 EST

Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

ANTXAN2 Therapeutics2026-03-17 20:00 EST

AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights

ANTXAN2 Therapeutics2026-08-11 20:00 EST

AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights

AVIRAtea2026-02-26 12:00 EST

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026

VIRIVirios Therapeutics2026-08-13 12:30 EST

Dogwood Therapeutics Announces Second Quarter 2026 Financial Results

ABUSArbutus2026-03-23 11:30 EST

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

AVIRAtea2026-03-05 21:05 EST

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

BRNSBarinthus Biotherapeutics2026-08-06 12:00 EST

Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments

View all latest news

Spero Therapeutics

Immunology and Inflammation Company Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious immune-mediated diseases. Its internal strategy now centers on CD40 ligand inhibition. SP001 SP001 is a third-generation, Fc-silent monoclonal antibody targeting CD40 ligand. The molecule is designed to...

Recent company news

SPROSpero Therapeutics2026-08-12 21:01 EST

Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update

SPROSpero Therapeutics2026-08-05 21:05 EST

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SPROSpero Therapeutics2026-08-04 21:01 EST

Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

SPROSpero Therapeutics2026-07-27 13:00 EST

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

SPROSpero Therapeutics2026-07-27 13:00 EST

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

Stock data

Close
1.19 USD
Market cap
163.86M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States